AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06507644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre irradiation of 3 hour
Description: A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 3 hour.
Study NCT06507644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical application of 8% methyl aminolevulinate photosensitizer MAL
Description: Participants will be treated with 8% topical MAL photosensitizer
Study NCT06507644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: topical application of 16% methyl aminolevulinate photosensitizer (MAL)
Description: Participants will be treated with 16% topical MAL photosensitizer
Study NCT06507644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical application of 16% methyl aminolevulinate photosensitizer (MAL)
Description: Participants will be treated with 16% topical MAL photosensitizer
Study NCT06507644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visible light source
Description: Skin illumination will be performed using a visible light source (LED) with a wavelength of 643 nm
Study NCT06507644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visible light source
Description: Skin illumination will be performed using a visible light source (LED) with a wavelength of 643 nm
Study NCT05594875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1921
Description: Subject will receive a single dose of SHR-1921 at dose level 1/2/3 on Day of each cycles
Study NCT06113289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Given by PO
Study NCT06113289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX029-01
Description: Given by PO
Study NCT05681585 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implementation support program
Description: The intervention consists of:~I Implementation strategies:~1.1 Ensuring leadership commitment 1.2 Responsive evaluation 1.3 Whole ward approach 1.4 Train the trainer model 1.5 Sustainability after the study~II Implementation interventions 2.1 Implementation team 2.2 ACP coordinator 2.3 Training and supervision: Kick-off, training of resource persons and health care personnel including practical exercises, network conferences 2.4 Toolkit and shared resources: ACP guideline, teaching material, information leaflets, documentation templates etc. 2.5 Structured fidelity measurements of the implementation level of a) the implementation interventions and b) the clinical intervention, with tailored feedback and supervision~III Clinical intervention: Advance Care Planning 3.1 Routine information and invitation to Advance Care Planning to all eligible patients 3.2 Written information to patients and relatives 3.3 Documentation and collaboration with other health care levels
Study NCT05552573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low-dose LYB001
Description: This vaccine is prepared through gene recombination and 3 doses of low-dose(30µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
Study NCT05552573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (CHO Cell)
Description: This vaccine is Positive-controlled vaccine and 3 doses (0.5ml) at the schedule of 0, 28, 56 days.
Study NCT05840718 — intervention group
Intervention type: DRUG
Intervention: Thiamin
Description: Patients in thiamine group received two daily dosis of 200 mg of thiamin diluted in 50 ml of 5% dextrose during 7 days
Study NCT05635071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib 100 MG [Ofev]
Description: Nintedanib 100mg bid \*15 days orally after hysteroscopic surgery
Study NCT05635071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 MG [Ofev]
Description: Nintedanib 150mg bid \*15 days orally after hysteroscopic surgery
Study NCT05769998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment-based treatment
Description: The ACT-based group intervention includes four 1-hour group sessions over two weeks. The treatment manual was developed by the authors of this study following the ACT framework and adapting materials and resources from ACT-based treatments developed for other settings. The focus of the intervention is to provide patients with pain education specific for patients who underwent TKA and to promote psychological flexibility. Each session employs experiential exercises, including mindfulness meditation, and metaphors addressing the core components of ACT.
Study NCT05769998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Standard pharmacotherapy and physical exercise plan provided to all the patients in the rehabilitation unit.
Study NCT05769998 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Standard pharmacotherapy and physical exercise plan provided to all the patients in the rehabilitation unit.
Study NCT05700318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neurostimulator
Description: The ShiraTronics Migraine Therapy System
Study NCT05552573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high-dose LYB001
Description: This vaccine is prepared through gene recombination and 3 doses of high-dose(60µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
Study NCT06443242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Dose Laser Acupuncture (LLA)
Description: The intervention utilizes the xS-998D06 semiconductor laser acupoint therapeutic device specifically designed for targeted acupoint therapy. This device is critical in delivering precise low-dose laser therapy at a controlled wavelength and power. The laser treatment is directed towards enhancing neurological function and potentially alleviating symptoms of insomnia and depression by stimulating specific acupoints associated with mental health and sleep.
Study NCT05361785 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMT
Description: FMT from healthy donor or placebo
Study NCT05361785 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: FMT
Description: FMT from healthy donor or placebo
Study NCT05378373 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Garmin, Pattern Health App
Description: Wearable sensors will deliver individualized feedback to participants according to their assigned intervention
Study NCT05378373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Garmin, Pattern Health App
Description: Wearable sensors will deliver individualized feedback to participants according to their assigned intervention
Study NCT05593471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity exercises
Description: resistance training progressively increasing according to specific criteria (10 repetitions maximum). for the major muscles of the body
Study NCT05593471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low intensity aerobic exercises
Description: low-intensity exercises performed using arm or leg ergometer machines
Study NCT06305104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 unit（U） EC
Description: 0.1 ml , one time, containing 5U of active ingredients
Study NCT05007782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denikitug
Description: Administered Intravenously
Study NCT05007782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered Intravenously
Study NCT06507254 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol Supplement
Description: Dietary supplement taken twice daily for 12 months.
Study NCT06507254 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: Dietary supplement taken twice daily for 12 months.
Study NCT06475989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06475989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06475989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study NCT06475989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06475989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06628609 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Passive recovery
Description: Volunteers laid in supine position resting for 30 minutes.
Study NCT06628609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBMT-sMF
Description: PBMT-sMF applied in the lower limbs with different doses per muscle group.
Study NCT06628609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shock wave
Description: Shock wave therapy applied in the lower limbs for 30 minutes.
Study NCT06628609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic compression
Description: Pneumatic compression applied in the lower limbs for 30 minutes.
Study NCT05853783 — intervention group
Intervention type: OTHER
Intervention: STRATICYTE™ Test
Description: Assessment for risk of progression to oral cancer
Study NCT04307849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Health Club
Description: Sexual health/HIV-related evidence-based interventions
Study NCT04307849 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Adolescent Health Club
Description: Sexual health/HIV-related evidence-based interventions
Study NCT04307849 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wait-list Control
Description: The wait-listed group will begin the intervention after the intervention group
Study NCT05133726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text4Support
Description: Daily supportive text messages
Study NCT05133726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer support
Description: Meeting with peers who have lived experiences with similar diagnoses but are in recovery
Study NCT06534541 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attentional bias to food cues
Description: Measurement of the amount of attention given to food cues
Study NCT04674826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab administered as 1 × X mL with Device A
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
Study NCT06443242 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser Acupuncture (SLA)
Description: Sham laser acupuncture serves as a control to assess the placebo effect of the laser treatment. It involves the same procedure as LLA but uses a non-emitting laser probe. This intervention is designed to mimic the LLA setup without delivering actual laser therapy, allowing for an evaluation of the psychological and physiological effects of the placebo compared to the active laser treatment.
Study NCT06443242 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard Medication Management (Control Group)
Description: This intervention involves the continued use of standard pharmacological treatment with SSRIs for managing symptoms of depression. It serves as a control to evaluate the effects of laser acupuncture against conventional medical treatment without the introduction of additional therapeutic modalities. Participants' adherence to their prescribed medication regimen is monitored and documented, ensuring an accurate comparison of treatment effects across groups.
Study NCT06443242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medication Management (Control Group)
Description: This intervention involves the continued use of standard pharmacological treatment with SSRIs for managing symptoms of depression. It serves as a control to evaluate the effects of laser acupuncture against conventional medical treatment without the introduction of additional therapeutic modalities. Participants' adherence to their prescribed medication regimen is monitored and documented, ensuring an accurate comparison of treatment effects across groups.
Study NCT05284422 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Peripheral venous catheter insertion
Description: Insertion of a short catheter in a peripheral vein with the help of visualization palpation
Study NCT05284422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided insertion of a peripheral venous catheter
Description: Insertion of a short catheter in a peripheral vein with the help of an ultrasound device
Study NCT06443242 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard Medication Management (Control Group)
Description: This intervention involves the continued use of standard pharmacological treatment with SSRIs for managing symptoms of depression. It serves as a control to evaluate the effects of laser acupuncture against conventional medical treatment without the introduction of additional therapeutic modalities. Participants' adherence to their prescribed medication regimen is monitored and documented, ensuring an accurate comparison of treatment effects across groups.
Study NCT04674826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tralokinumab administered as 2 × Y mL with Device B
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
Study NCT05533437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry needling
Description: the dry needle inserted to area of pain
Study NCT06534034 — intervention group
Intervention type: PROCEDURE
Intervention: Dental implant placement
Description: Dental implant placement on edentulous jaw.
Study NCT05533437 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio taping
Description: kinesio taping
Study NCT05392257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab + zanubrutinib + lenalidomide
Description: Rituximab at 375mg / m2, Day 0; Zanubrutinib 160mg bid continuously oral; Lenalidomide 25mg qd oral on days 1-21; 28 days as a course of treatment
Study NCT03845751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIFU hemi-ablation combined with ADT.
Description: Hemi-ablation of the cancer-harbouring prostatic lobe will be carried out using HIFU energy. Short-term 3-month ADT will be administered concomitantly. Short-term ADT is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone \[LHRH\] agonist). The ADT protocol starts within 1 month prior to the scheduled HIFU session
Study NCT05306431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide
Description: Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant
Study NCT06475989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabrafenib
Description: Given PO
Study NCT06475989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05306431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hypochlorite
Description: A number of irrigant solution has thus been proposed to serve the purpose, the most popular being sodium hypochlorite (NaOCl) because of its excellent antimicrobial activity but also the ability to dissolve organic matter
Study NCT05078242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EaseVRx
Description: Participants will experience 7 sessions of the EaseVRx device for chronic pain.
Study NCT06475989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06475989 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary study
Study NCT06475989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary study
Study NCT06475989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trametinib
Description: Given PO
Study NCT06207669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy will be applied to individuals in the clinic for 30 minutes after the 2nd hour of each hemodialysis session for 4 weeks.
Study NCT06331130 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography
Description: Computed Tomography done according to Clinical Practice to assess mesenteric involvment
Study NCT06222658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pharmaco-mechanichal thrombectomy
Description: pharmaco-mechanichal thrombectomy in acute limb ischemia
Study NCT04622267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barbed suture
Description: to close a C-section incision
Study NCT04622267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard antimicrobial suture
Description: to close a C-section incision
Study NCT03508479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RG-HRV16
Description: 0.25 mL inoculum intranasally delivered into each nostril (0.5 mL total delivered). Total cumulative dose of 1000 median tissue culture infective dose at 50% of cells inoculated (TCID50).
Study NCT05781503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identity Capital Intervention (Coach + Co-designed Leadership Guide)
Description: Young people randomized to the intervention group will engage in a co-designed leadership guide with their assigned coach. The co-designed leadership guide contains 12 chapters with the overarching aim of enhancing identity capital along with providing strategies to achieve participant-identified goals. Each chapter contains four activities (e.g., self-reflection exercise or listening to a podcast). Ideally, youth will complete one chapter every month. Each young person in this group will meet individually with their coach every two weeks and with a larger group of 10 youth participants and their coach every month.
Study NCT05781503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly Rent Subsidies
Description: All study participants will receive a monthly rent subsidy ($800 for those living in Toronto; $700 for those living in St. Catharine's or Hamilton due to differences in cost of living) for 12 months.
Study NCT05781503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monthly Rent Subsidies
Description: All study participants will receive a monthly rent subsidy ($800 for those living in Toronto; $700 for those living in St. Catharine's or Hamilton due to differences in cost of living) for 12 months.
Study NCT04722809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Description: Injection in the temporal and masseter muscles: in 3 points in the masseter muscles and in 2 points in the temporal muscles.
Study NCT04722809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QOL-Brux
Description: Questionnaire evaluating the symptoms of bruxism Inclusion and 3 months post-injection
Study NCT04722809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscular strength of the jaw
Description: Measurement in the jaw with a dynamometer connected to a sensor placed on the 1st molar on the right side.~At inclusion and 1 month post-injection.
Study NCT04722809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensity and frequency of episodes of nocturnal bruxism
Description: Measurements via a portable electromyography system, coupled with a heartbeat sensor (Bruxoff®). Measurements performed during normal sleeping conditions at home before injection and 1 month after.
Study NCT04867057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichomylin for SAD
Description: Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
Study NCT04867057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SAD
Description: Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
Study NCT04867057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichomylin for MAD
Description: Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
Study NCT04867057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MAD
Description: Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.